» Articles » PMID: 38019700

SARS-CoV-2 Infection and Effects of Age, Sex, Comorbidity, and Vaccination Among Older Individuals: A National Cohort Study

Abstract

Background: We investigated the contribution of age, coexisting medical conditions, sex, and vaccination to incidence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and of severe, critical, or fatal COVID-19 in older adults since pandemic onset.

Methods: A national retrospective cohort study was conducted in the population of Qatar aged ≥50 years between February 5, 2020 and June 15, 2023. Adjusted hazard ratios (AHRs) for infection and for severe coronavirus disease 2019 (COVID-19) outcomes were estimated through Cox regression models.

Results: Cumulative incidence was 25.01% (95% confidence interval [CI]: 24.86-25.15%) for infection and 1.59% (95% CI: 1.55-1.64%) for severe, critical, or fatal COVID-19 after a follow-up duration of 40.9 months. Risk of infection varied minimally by age and sex but increased significantly with coexisting conditions. Risk of infection was reduced with primary-series vaccination (AHR: 0.91, 95% CI: 0.90-0.93) and further with first booster vaccination (AHR: 0.75, 95% CI: 0.74-0.77). Risk of severe, critical, or fatal COVID-19 increased exponentially with age and linearly with coexisting conditions. AHRs for severe, critical, or fatal COVID-19 were 0.86 (95% CI: 0.7-0.97) for one dose, 0.15 (95% CI: 0.13-0.17) for primary-series vaccination, and 0.11 (95% CI: 0.08-0.14) for first booster vaccination. Sensitivity analysis restricted to only Qataris yielded similar results.

Conclusion: Incidence of severe COVID-19 in older adults followed a dynamic pattern shaped by infection incidence, variant severity, and population immunity. Age, sex, and coexisting conditions were strong determinants of infection severity. Vaccine protection against severe outcomes showed a dose-response relationship, highlighting the importance of booster vaccination for older adults.

Citing Articles

Addressing bias in the definition of SARS-CoV-2 reinfection: implications for underestimation.

Chemaitelly H, Ayoub H, Tang P, Yassine H, Al Thani A, Hasan M Front Med (Lausanne). 2024; 11:1363045.

PMID: 38529118 PMC: 10961414. DOI: 10.3389/fmed.2024.1363045.


SARS-CoV-2 infection and effects of age, sex, comorbidity, and vaccination among older individuals: A national cohort study.

Mahmoud M, Ayoub H, Coyle P, Tang P, Hasan M, Yassine H Influenza Other Respir Viruses. 2023; 17(11):e13224.

PMID: 38019700 PMC: 10663173. DOI: 10.1111/irv.13224.

References
1.
Chemaitelly H, Faust J, Krumholz H, Ayoub H, Tang P, Coyle P . Short- and longer-term all-cause mortality among SARS-CoV-2- infected individuals and the pull-forward phenomenon in Qatar: a national cohort study. Int J Infect Dis. 2023; 136:81-90. DOI: 10.1016/j.ijid.2023.09.005. View

2.
Mahmoud M, Ayoub H, Coyle P, Tang P, Hasan M, Yassine H . SARS-CoV-2 infection and effects of age, sex, comorbidity, and vaccination among older individuals: A national cohort study. Influenza Other Respir Viruses. 2023; 17(11):e13224. PMC: 10663173. DOI: 10.1111/irv.13224. View

3.
Altarawneh H, Chemaitelly H, Hasan M, Ayoub H, Qassim S, Almukdad S . Protection against the Omicron Variant from Previous SARS-CoV-2 Infection. N Engl J Med. 2022; 386(13):1288-1290. PMC: 8849180. DOI: 10.1056/NEJMc2200133. View

4.
Singhal S, Kumar P, Singh S, Saha S, Dey A . Clinical features and outcomes of COVID-19 in older adults: a systematic review and meta-analysis. BMC Geriatr. 2021; 21(1):321. PMC: 8133052. DOI: 10.1186/s12877-021-02261-3. View

5.
Bartleson J, Radenkovic D, Covarrubias A, Furman D, Winer D, Verdin E . SARS-CoV-2, COVID-19 and the Ageing Immune System. Nat Aging. 2021; 1(9):769-782. PMC: 8570568. DOI: 10.1038/s43587-021-00114-7. View